Search results for "comorbidity."

showing 10 items of 796 documents

The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study…

2010

Abstract Background Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel antipsychotic drugs) on cognitive performance over time. Methods In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (n = 13) or novel a…

AdultMalemedicine.medical_specialtyCognition disorderslcsh:RC435-571Teràpia cognitivamedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticPilot ProjectsComorbidityCognitive therapyNeuropsychological TestsTrastorns de la cogniciólcsh:PsychiatryResearch articlemedicineHumansVerbal fluency testLongitudinal StudiesAntipsychotic drugsEffects of sleep deprivation on cognitive performancePsychiatryAntipsychoticRetrospective StudiesPsychiatric Status Rating ScalesCognitionExecutive functionsmedicine.diseasePsychiatry and Mental healthTreatment OutcomeSchizophreniaSchizophreniaFemaleSchizophrenic PsychologyAntipsicòticsEsquizofrèniaVerbal memoryCognition DisordersPsychologyAntipsychotic AgentsClinical psychologyBMC Psychiatry
researchProduct

A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depress…

2017

Abstract Background Early Improvement of depressive symptoms within two weeks of antidepressant treatment is a highly sensitive but less specific predictor of later treatment outcome. The aim of this study was to identify clinical features at treatment initiation which are associated with early improvement and non-improvement as well as to identify variables predicting non-remission in patients showing an early improvement. Methods 889 patients with a major depressive episode according to DSM-IV who had participated in an antidepressant treatment trial served as study sample. Clinical predictors (demographic variables, psychopathology, comorbid disorders) were analysed in 698 (79%) early im…

AdultMalemedicine.medical_specialtyComorbidityAvoidant personality disorderPatient ReadmissionSeverity of Illness IndexSuicidal Ideation03 medical and health sciences0302 clinical medicineRisk FactorsRating scaleInternal medicinemedicineHumansMajor depressive episodePsychiatryAtypical depressionDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptombusiness030217 neurology & neurosurgeryPsychopathologyJournal of Affective Disorders
researchProduct

Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response

2019

Obesity is one of the most prevalent somatic comorbidities of Major Depressive Disorder (MDD). We aimed to investigate the relationship between body mass index (BMI) and MDD, the symptomatology of the disorder as well as the outcome of antidepressant treatment.Early medication change (EMC) trial participants with BMI measurement (n = 811) were categorized according to WHO-criteria in normal or low weight (BMI  25), overweight (25- 30), and obese (≥30). Depression severity and BMI was assessed in weekly intervals up to 8 weeks. BMI at baseline and course of BMI during the study were investigated in linear regression models as possible moderators of therapy response. Possible moderators such …

AdultMalemedicine.medical_specialtyComorbidityOverweightWeight GainBody Mass IndexDepressive symptomatology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansObesityDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseObesityAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyAntidepressantMajor depressive disorderFemalemedicine.symptombusinessWeight gainBody mass index030217 neurology & neurosurgeryJournal of Affective Disorders
researchProduct

Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smok…

2007

Aims: To assess the role of smoking on treatment outcome in quitting alcoholics on the background of the priming or coping hypothesis (Rohsenow et al. , [1997][1]). Methods: Data sets of placebo treated patients of the German phase III trial of naltrexone (Gastpar et al. , [2002][2]) and of acamprosate treated patients of a German phase IV trial Soyka et al. , [2002][3]) were reanalyzed. Differences between smoking and non-smoking alcoholics were evaluated using χ2-, t - or ANOVA-tests, relapse rates using survival techniques with Cox regression. Results: Smoking alcoholics differed significantly from non-smoking alcoholics regarding sociodemographic variables (e.g. more males, more often l…

AdultMalemedicine.medical_specialtyCoping (psychology)TaurineAcamprosateNarcotic AntagonistsTemperanceComorbidityPlaceboPhase IV TrialSeverity of Illness IndexNaltrexonePharmacotherapySex FactorsRecurrenceInternal medicinemedicineOdds RatioHumansPsychiatryProportional Hazards Modelsbusiness.industryProportional hazards modelSmokingGeneral MedicineMiddle AgedNaltrexoneClinical trialAlcoholismAcamprosateTreatment OutcomeMultivariate AnalysisFemalebusinessmedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic …

2020

<b><i>Purpose:</i></b> The coronavirus disease 2019 (COVID-19) pandemic is disrupting urology health-care worldwide. Reduced emergency room visits resulting in adverse outcomes have most recently been reported in pediatrics and cardiology. We aimed to compare patients with emergency room visits for pyelonephritis in 2019 (pre-COVID-19 era) and within the first wave of pandemic in 2020 (COVID-19 era) with regard to the number of visits and severe adverse disease outcomes. <b><i>Methods:</i></b> We performed a retrospective multicentre study comparing characteristics and outcomes of patients with pyelonephritis, excluding patients with hydroneph…

AdultMalemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Adverse outcomesUrologymedicine.medical_treatment030232 urology & nephrologyUrologyComorbiditySide effect03 medical and health sciencesYoung Adult0302 clinical medicineInformation campaignGermanyPandemicmedicineHumansHydronephrosisPandemicsStone diseaseRetrospective StudiesOutcomePyelonephritisbusiness.industrySARS-CoV-2IncidenceCOVID-19Middle Agedmedicine.diseaseNephrectomyHospitalizationCoronavirus030220 oncology & carcinogenesis2019-nCoVCollateral damageFemaleMorbiditybusinessEmergency Service HospitalResearch ArticleUrinary infectionUrologia internationalis
researchProduct

Prevalence, predictors and comorbidity of dry skin in the general population

2018

Background Dry skin is a frequent and multifaceted condition which can be associated with skin irritation, itch, patient discomfort and manifest skin disease. In spite of being frequent, little is known about the epidemiology of dry skin in the population. Objective To determine the prevalence of dry skin in the German adult population. Methods Data of 48 630 employed persons were assessed on a cross-sectional level in whole-body examinations by experienced dermatologists during company-based skin screenings conducted in 343 German companies. Next to the current dermatologic findings, age, gender, allergies, atopic diseases and the skin type were assessed. Results In total, n = 14 300 perso…

AdultMalemedicine.medical_specialtyCross-sectional studyPopulationPrevalenceDermatologySkin DiseasesDermatitis Atopic030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineGermanyPsoriasisDry skinHypersensitivityPrevalencemedicineHumansPsoriasis030212 general & internal medicineeducationeducation.field_of_studybusiness.industryAge FactorsSeborrhoeic dermatitisAtopic dermatitisMiddle Agedmedicine.diseaseDermatologyComorbidityDermatitis SeborrheicCross-Sectional StudiesInfectious DiseasesFemaleWartsmedicine.symptombusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Prevalence of psychiatric disorders in an onset cohort of adults with type 1 diabetes

2003

Previous studies indicate a high prevalence of psychiatric disorders in adults with type 1 diabetes mellitus. The aim of our study was to determine if newly diagnosed adults with type 1 diabetes already have an elevated rate of psychiatric disorders at the beginning of their physical illness.The authors consecutively recruited 313 newly diagnosed, adult inpatients with type 1 diabetes (age 17-40 years) from 12 hospitals. A national, representative population sample of 2046 persons of a similar age range served as the reference group. Psychiatric disorders were measured in both groups using structured interviews that provided diagnoses according to DSM-IV.There was a point prevalence of 12.5…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismEndocrinologyReference ValuesGermanyImmunopathologyDiabetes mellitusEpidemiologyPrevalenceInternal MedicinemedicineHumansHypoglycemic AgentsInsulinOccupationsPsychiatryInpatientsType 1 diabetesMarital Statusbusiness.industrymedicine.diseaseComorbidityDiabetes Mellitus Type 1Psychotic DisordersStructured interviewCohortEducational StatusMarital statusFemalebusinessDiabetes/Metabolism Research and Reviews
researchProduct

Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia

2019

Objective Epstein-Barr virus (EBV)-associated gastric cancer has been proposed to be a distinct gastric cancer molecular subtype. The prognostic significance of EBV infection in gastric cancer remains unclear and needs further investigation. Our study aimed to analyze EBV-positive and EBV-negative gastric cancer patients regarding their personal and tumor-related characteristics, and compare their overall survival. Methods Gastric cancer patients consecutively treated at the Riga East University Hospital during 2009-2016 were identified retrospectively. Tumor EBV status was determined by in-situ hybridization for EBV-encoded RNA (EBER). Information about clinicopathological characteristics …

AdultMalemedicine.medical_specialtyEpstein-Barr Virus InfectionsComorbidityKaplan-Meier EstimateAdenocarcinomaGastroenterologyHospital recordsArticle03 medical and health sciencesYoung Adult0302 clinical medicineAge DistributionStomach NeoplasmsInternal medicinehemic and lymphatic diseasesmedicineHumansStage (cooking)Sex DistributionAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overHepatologyStage I Gastric Cancerbusiness.industryHazard ratioSmokingGastroenterologyCancerEpstein-Barr Virus PositiveMiddle AgedOverweightUniversity hospitalmedicine.diseasePrognosisLatviaConfidence intervalSurvival Rate030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleNeoplasm Gradingbusiness
researchProduct

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leu…

2015

Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days 2-3) in 93 patients aged 18-60 years refractory to one cycle of induction therapy. Primary end point of the study was response to therapy; secondary end points included evaluation of toxicities, in particular, rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell tr…

AdultMalemedicine.medical_specialtyGemtuzumab ozogamicinmedicine.medical_treatmentSalvage therapyTretinoinComorbidityKaplan-Meier EstimateAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansSalvage TherapyMitoxantroneChemotherapybusiness.industryRemission InductionCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyArticlesMiddle Agedmedicine.diseaseGemtuzumab3. Good healthSurgeryTransplantationConsolidation ChemotherapyLeukemiaLeukemia Myeloid AcuteAminoglycosidesTreatment Outcome030220 oncology & carcinogenesisCytarabineFemaleMitoxantronebusiness030215 immunologymedicine.drugHaematologica
researchProduct

Comorbid Internet Addiction in Male Clients of Inpatient Addiction Rehabilitation Centers

2013

Addictive Internet use has recently been proposed to be included in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Still, little is known about its nosological features, including comorbidity with other mental disorders and disorder-specific psychopathological symptoms. To investigate whether Internet addiction (IA) is an issue in patients in addiction treatment, 1826 clients were surveyed in 15 inpatient rehabilitation centers. Male patients meeting criteria for comorbid IA (n = 71) were compared with a matched control group of male patients treated for alcohol addiction without addictive Internet use (n = 58). The SCL-90-R, the Patient Health Questionnaire, and …

AdultMalemedicine.medical_specialtyGeneralized anxiety disorderAdolescentmedia_common.quotation_subjectComorbidityYoung Adultmental disordersmedicineHumansPsychiatryDepression (differential diagnoses)Agedmedia_commonInternetbusiness.industryMental DisordersAddictionMiddle Agedmedicine.diseaseComorbidityBehavior AddictivePatient Health QuestionnaireAlcoholismPsychiatry and Mental healthAddiction medicineSubstance Abuse Treatment CentersbusinessPsychosocialPsychopathologyClinical psychologyJournal of Nervous & Mental Disease
researchProduct